? The UCSF HIV Clinical Trials Unit (CTU) will study treatment of HIV and its complications and prevention of HIV transmission in resource rich and poor settings through the ACTG and IMPAACT networks. This newly formed CTU creates a dynamic research agenda spanning pediatric to adult disease and features accomplished and innovative researchers, a cross-cutting research agenda, HIV infected clinic populations totaling 14,000, experienced clinical trials staff, strong mentoring programs and community participation. ? Dr. Havlir, chief of the HIV/AIDS Division at San Francisco General Hospital will direct the CTU and lead the adult UCSF Clinical Research Site (CRS) affiliated with ACTG; Dr. Wara will lead the pediatric, adolescent and pregnant women CRS, working through IMPAACT; Dr. Kamya will lead the adult CRS of Makerere University/Infectious Diseases Institute in Uganda, as a site for the ACTG. Our CTU contributions will occur in the NIH high priority research areas of optimization of clinical management and co-morbidities; translational research/drug development; prevention of mother to child transmission and vaccines. We will closely collaborate with the VTN/HPTN-affiliated San Francisco Department of Public Health prevention CTU in promoting a coordinated approach to prevention and treatment research in our community. Our goals: ? ? Aim 1: Design and conduct research to define simple, safe and lifelong antiretroviral treatment (ART) strategies for children and adults; new drugs and novel agents including vaccines for HIV and its complications; innovative approaches to treat HIV co-morbidities such as TB, malaria, HPV, hepatitis B and C, and studies of viral dynamics, reservoirs, and genomics to understand pharmacokinetics and treatment responses in HIV infected participants enrolled from CRS sites at UCSF and Makerere University.
Aim 2. Integrate the HIV treatment and prevention research agenda at the scientific, operational and community level by catalyzing scientific exchange, operations, and community outreach between prevention and treatment groups, testing novel strategies to prevent vertical and horizontal transmission.
Aim 3. Foster the development of the next generation of patient based researchers by mentoring junior investigators, leveraging support of existing funding training programs such as Fogarty and CFAR.
Aim 4. Conduct research with community-based input and outreach through vibrant community advisory boards and CTU support of community education and dissemination of research findings. ? ? The relevance of this research is that the studies will define new standards for the treatment of HIV disease and its complications and will improve ways to prevent transmission of HIV from mother to child. ? ? ADMINISTRATIVE COMPONENT: ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI069502-01
Application #
7095773
Study Section
Special Emphasis Panel (ZAI1-MH-A (M1))
Program Officer
Welsch, Sue A
Project Start
2007-01-01
Project End
2013-11-30
Budget Start
2007-01-01
Budget End
2007-11-30
Support Year
1
Fiscal Year
2007
Total Cost
$1,254,022
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 92 publications